Hepatitis Monthly
Zhuang Fangcheng4,*, 
Wang Xuanyi2, Chen Mingding3, Jiang Liming4, Wu Jie4, Jiang Qi5, Gong Yuanping6, Qian Wen1, Xin Yajuan1, Mao Jiangsen4Hepatitis A was ranked first among all of the different types of viral hepatitis in China, which occurred an average of 500,000 cases annually during the 1980s. A live attenuated hepatitis A vaccine was applied in preventing of the disease in 1992, large scale used in vaccination program in 1995, and incorporated in the Expanded Program of Immunization in 2008 in China.
The objective of this study was to determine whether, and to what extent, the decline in the incidence of hepatitis A in China was the result of hepatitis A (HA) vaccination.
Official documents and longitudinal serological follow-up studies were reviewed to compare the incidence of HA before and after the introduction of the vaccine.
National trends in the incidence of HA in China saw rates decrease by 92.7% in 2009, compared to the levels seen in 1992. A mass vaccination program was carried out in 3-18 year old children (Wuhan City, China), and its protective efficacy was 85.4%. In a mass vaccination program of an entire population (Shenshi County, China), the annual HA incidence decreased from 359.7/100,000 to 17.7/100,000 (almost 20.3 times). There was a significant relationship found between vaccine coverage and the incidence of HA, the correlation of the negative regression was significant at the 1% (Kendall rank correlation, significant level P < 0.05).
In summary, this study highlights the important role of implementing a vaccination program in decreasing the incidence of HA, and the large protective efficacy of such a strategy, as demonstrated in China
© 2012, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Afsharian M, Ghaderi M, Vaziri S, Leghaei Z, Ghadiri K, et al. Seroconversion rates after hepatitis-B vaccination in children. J Kermanshah Univ Med Sci. 2012;15(6):e78901. doi:
Nalbantoglu B, M.Donma M, Ozdilek B, Karasu E, Nalbantoglu A. Shifting Epidemiology of Hepatitis A Infection and Vaccination Status of Children Aged 6 Months-12 Years: Time for Mass Vaccination. Inn J Pediatr. 2013;23(3):. doi:
Saffar H, Ajami A, Saffar MJ, Shojaei J, Sotudeh-Anvari M, et al. Prevalence of Hepatitis B Virus Seromarkers in Young Adults Vaccinated at Birth; Impact on the Epidemiology of Hepatitis B Infection in Iran. Hepat Mon. 2014;14(5):e17263. doi: https://doi.org/10.5812/hepatmon.17263
Norouzirad R, Shakurnia AH, Assarehzadegan M, Serajian A, Khabazkhoob M. Serum Levels of Anti-Hepatitis B Surface Antibody Among Vaccinated Population Aged 1 to 18 Years in Ahvaz City Southwest of Iran. Hepat Mon. 2014;14(1):e13625. doi: https://doi.org/10.5812/hepatmon.13625
Aminian O, Moaven Saidi M, Sadeghniiat Haghighi K, Izadi N. Coverage and Long-Term Immunogenicity of Hepatitis B Vaccine in Healthcare Workers. Arch Clin Infect Dis. 2016;11(4):e35758. doi: https://doi.org/10.5812/archcid.35758
Ordering Reprints
Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC
Author(s):
